Spots Global Cancer Trial Database for Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Official Title: A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer
Study ID: NCT04131192
Conditions
Study Description
Brief Summary: This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.
Detailed Description: This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.This phase IB trial is Multi-center and open。
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jiangsu Province Hospital, Nanjing, China/jiangsu, China
shandong Cancer Hospital, Jinan, China/shandong, China
Contact Details
Name: shu zhang
Affiliation: Shandong Cancer Hospital and Institute
Role: PRINCIPAL_INVESTIGATOR
Name: lianke liu
Affiliation: The First Affiliated Hospital with Nanjing Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
